These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 2136311

  • 1. Serum ferritin, iron and transferrin in women with thyrotoxic Graves' disease before and after methimazole treatment.
    Zwirska-Korczala K, Buntner B, Sobieraj H, Ostrowska Z, Kniazewski B, Swietochowska E.
    Acta Physiol Pol; 1990; 41(7):163-8. PubMed ID: 2136311
    [Abstract] [Full Text] [Related]

  • 2. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM, Lima N, Knobel M, Cavaliere H, Medeiros-Neto G.
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [Abstract] [Full Text] [Related]

  • 3. [Serum thyroxine and triiodothyronine levels after a single dose and after 2-month-long thiamazole treatment of Graves' disease with reference to drug's pharmacokinetics].
    Syrenicz A.
    Ann Acad Med Stetin; 1990 Feb; 36():133-52. PubMed ID: 2099104
    [Abstract] [Full Text] [Related]

  • 4. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P.
    Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
    [Abstract] [Full Text] [Related]

  • 5. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS, Kuo SW.
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Methimazole protection against oxidative stress induced by hyperthyroidism in Graves disease.
    Sewerynek J, Wiktorska J, Nowak D, Lewinski A.
    Endocr Regul; 2000 Jun; 34(2):83-9. PubMed ID: 10911409
    [Abstract] [Full Text] [Related]

  • 8. Factors influencing the relationship between labelled triiodothyronine and thyroxine levels in the serum of patients with Graves' disease.
    Földes J, Gyertyánfy G, Tako J, Bános C, Gesztesi E.
    Endokrinologie; 1973 Jan; 61(1):52-64. PubMed ID: 4739850
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
    Molnár I.
    Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
    [Abstract] [Full Text] [Related]

  • 11. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
    Zwirska-Korczala K, Berdowska A, Jochem J, Sitkiewicz A, Birkner E, Polaniak R, Jedrzejowska-Szypułka H, Korzonek-Szlacheta I.
    J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
    [Abstract] [Full Text] [Related]

  • 12. [Concentration of ferritin, transferrin and iron as a markers of iron deficiency in healthy women in reproductive age].
    Chełchowska M, Laskowska-Klita T, Leibschang J.
    Pol Merkur Lekarski; 2007 Jan; 22(127):25-7. PubMed ID: 17477085
    [Abstract] [Full Text] [Related]

  • 13. Serum ferritin as an assessment of iron stores and other hematologic parameters during pregnancy.
    Kaneshige E.
    Obstet Gynecol; 1981 Feb; 57(2):238-42. PubMed ID: 7465131
    [Abstract] [Full Text] [Related]

  • 14. Supplementation with antioxidants in the treatment of Graves' disease; the effect on glutathione peroxidase activity and concentration of selenium.
    Vrca VB, Skreb F, Cepelak I, Romic Z, Mayer L.
    Clin Chim Acta; 2004 Mar; 341(1-2):55-63. PubMed ID: 14967159
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Serum iron parameters in chronic hepatitis C patients and comparison of the results before and during antiviral treatment].
    Bolewska B, Wojtacha A, Juszczyk J, Przedwojewski M.
    Pol Merkur Lekarski; 2005 May; 18(107):552-5. PubMed ID: 16161954
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A case of total thyroxine-binding globulin deficiency with Graves' disease: fluctuations of plasma triiodothyronine/thyroxine ratio.
    Kamikubo K, Kojima N, Yamakita N, Miura K.
    Jpn J Med; 1986 May; 25(2):186-90. PubMed ID: 3091890
    [Abstract] [Full Text] [Related]

  • 20. Serum soluble CD8 concentration is an indicator of disease activity in patients with Graves' disease.
    Balázs C, Bokk A, Farid NR.
    Thyroid; 1994 May; 4(1):27-30. PubMed ID: 8054859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.